← Back to Search

evaluation of alpha synuclein aggregates in the brain for Multiple System Atrophy

Q: What is the current number of individuals being recruited for participation in this clinical research study?

Indeed, the information available on clinicaltrials.gov indicates that this particular clinical trial is currently seeking eligible participants. The initial posting of the trial occurred on January 1st, 2024, and it underwent its most recent revision on December 29th, 2023. In order to complete the study successfully, a total of 40 patients will be recruited from one designated location.

Q: Is the age criterion for participation in this study limited to individuals below 55 years of age?

The eligibility criteria for patient enrollment in this clinical trial require individuals to be older than 50 years and younger than 80 years.

Q: Are there any ongoing efforts to enlist participants for this research study at the moment?

Indeed, the data provided on clinicaltrials.gov confirms that this trial is actively seeking individuals to participate. The initial posting of the clinical trial occurred on January 1st, 2024 and it was most recently updated on December 29th, 2023. A total of 40 participants will be enrolled at a single location.

Phase < 1

Recruiting

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Hoehn and Yahr stage I-IV

Have an existing diagnosis of idiopathic PD, using consensus criteria

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up tp 120 minutes

Awards & highlights

Study Summary

This trial aims to test the use of a radioactive substance called [11C]SY08 with PET imaging to detect a protein called alpha synuclein in people with Parkinson's disease, multiple system at

Who is the study for?

This trial is for individuals aged 50-80 with Parkinson's Disease, Multiple System Atrophy, or Lewy Body Dementia. Participants must be able to consent, speak English, and have a partner to assist with assessments. They should be on stable medications for at least 30 days.Check my eligibility

What is being tested?

[11C]SY08 is being tested as a PET radiotracer in patients with brain alpha-synuclein aggregates and healthy controls. The study will assess how the tracer distributes and moves in the brain after an intravenous injection.See study design

What are the potential side effects?

As this trial involves imaging rather than medication or therapy intervention, side effects are expected to be minimal but may include discomfort from the injection or reactions related to lying still during PET/MRI scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My Parkinson's disease is between stages I and IV.

Select...

I have been diagnosed with Parkinson's disease by a doctor.

Select...

I have been diagnosed with multiple system atrophy (MSA).

Select...

I am between 50 and 80 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up tp 120 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up tp 120 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up tp 120 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

brain uptake evaluation

Trial Design

1Treatment groups

Experimental Treatment

Group I: evaluation of alpha synuclein aggregates in the brainExperimental Treatment1 Intervention

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,934 Previous Clinical Trials

13,198,541 Total Patients Enrolled

4 Trials studying Multiple System Atrophy

2,025 Patients Enrolled for Multiple System Atrophy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of individuals being recruited for participation in this clinical research study?

"Indeed, the information available on clinicaltrials.gov indicates that this particular clinical trial is currently seeking eligible participants. The initial posting of the trial occurred on January 1st, 2024, and it underwent its most recent revision on December 29th, 2023. In order to complete the study successfully, a total of 40 patients will be recruited from one designated location."

Answered by AI

Is the age criterion for participation in this study limited to individuals below 55 years of age?

"The eligibility criteria for patient enrollment in this clinical trial require individuals to be older than 50 years and younger than 80 years."

Answered by AI

Are there any ongoing efforts to enlist participants for this research study at the moment?

"Indeed, the data provided on clinicaltrials.gov confirms that this trial is actively seeking individuals to participate. The initial posting of the clinical trial occurred on January 1st, 2024 and it was most recently updated on December 29th, 2023. A total of 40 participants will be enrolled at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET Imaging Evaluation of [11C]SY08

Changning Wang 2024. "PET Imaging Evaluation of [11C]SY08". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06098612.

All > Dementia With Lewy Bodies